Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.13% |
| 2 | Technology | 13.55% |
| 3 | Financials | 11.85% |
| 4 | Consumer Staples | 10.18% |
| 5 | Industrials | 9.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
401
HEICO Corp Class A
HEI.A
$37.5B
| $46.7M | 0.06% |
1,470,527
+195,947
| +15% | +$6.11M |
|
|
MODV
402
DELISTED
ModivCare
MODV
| $46.5M | 0.06% |
918,900
+23,200
| +3% | +$1.07M |
|
|
DENN
403
DELISTED
Denny's
DENN
| $46.5M | 0.06% |
3,946,911
+352,600
| +10% | +$4.22M |
|
404
Morningstar
MORN
$7.33B
| $46.3M | 0.06% |
591,100
+4,900
| +0.8% | +$370K |
|
|
SIX
405
DELISTED
Six Flags Entertainment Corp.
SIX
| $46.1M | 0.06% |
773,100
+1,100
| +0.1% | +$66.5K |
|
406
Pan American Silver
PAAS
$22.2B
| $46M | 0.06% |
2,736,800
-476,617
| -15% | -$8.24M |
|
|
GRA
407
DELISTED
W.R. Grace & Co.
GRA
| $45.8M | 0.06% |
635,900
+6,600
| +1% | +$463K |
|
408
Box
BOX
$4.52B
| $45.8M | 0.06% |
2,510,200
+965,800
| +63% | +$17.4M |
|
409
Stanley Black & Decker
SWK
$15.5B
| $45.7M | 0.06% |
325,062
-800
| -0.2% | -$110K |
|
410
General Dynamics
GD
$106B
| $45.7M | 0.06% |
+230,900
| New | +$45.2M |
|
|
VRE
411
DELISTED
Veris Residential
VRE
| $45.7M | 0.06% |
1,682,201
+307,701
| +22% | +$8.44M |
|
|
SSRI
412
DELISTED
Silver Standard Resources
SSRI
| $45.6M | 0.06% |
4,699,883
+47,200
| +1% | +$474K |
|
413
Nasdaq
NDAQ
$53.2B
| $45.6M | 0.06% |
1,913,424
+149,724
| +8% | +$3.44M |
|
414
FIVE9
FIVN
$2.35B
| $45.5M | 0.06% |
2,113,600
+132,100
| +7% | +$2.71M |
|
415
Skywest
SKYW
$4.18B
| $45.5M | 0.06% |
1,295,700
+117,700
| +10% | +$4.13M |
|
|
RPXC
416
DELISTED
RPX Corporation
RPXC
| $45.3M | 0.06% |
3,243,810
+468,910
| +17% | +$6.23M |
|
|
SPPI
417
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
| $45.2M | 0.06% |
6,071,817
+392,017
| +7% | +$2.56M |
|
|
ELME
418
Elme Communities
ELME
$145M
| $44.9M | 0.06% |
1,408,500
+350,200
| +33% | +$11.3M |
|
419
Perdoceo Education
PRDO
$1.94B
| $44.9M | 0.06% |
4,680,062
-47,900
| -1% | -$467K |
|
420
Madison Square Garden
MSGS
$9.93B
| $44.9M | 0.06% |
319,376
+159,688
| +100% | +$22.6M |
|
421
Grupo Aeroportuario del Pacifico
PAC
$12.7B
| $44.8M | 0.06% |
399,200
+20,500
| +5% | +$2.14M |
|
|
SRCL
422
DELISTED
Stericycle Inc
SRCL
| $44.8M | 0.06% |
586,720
-138,300
| -19% | -$11.4M |
|
423
Leidos
LDOS
$17.5B
| $44.7M | 0.06% |
865,050
-140,300
| -14% | -$7.47M |
|
|
GOOD
424
Gladstone Commercial Corp
GOOD
$627M
| $44.7M | 0.06% |
2,050,300
+79,100
| +4% | +$1.69M |
|
425
Waterstone Financial
WSBF
$377M
| $44.5M | 0.06% |
2,358,581
-43,993
| -2% | -$828K |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 15% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.